News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cubist Pharmaceuticals, Inc. (CBST) Strikes Agreement With Competitor To Delay Generic Cubicin



7/24/2014 7:04:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A competitor of antibiotics maker Cubist Pharmaceuticals has agreed not to launch a generic version of its flagship drug for skin infections until at least Dec. 1 while a judge decides on a patent challenge.

In 2012, Illinois-based Hospira indicated it hopes to launch a generic of Cubicin, claiming the patents are invalid. Cubicin remains Cubist’s biggest money-maker, contributing 80 percent of the company’s revenue in the three months that ended in June. The Lexington drug maker has sued Hospira, claiming patent infringement.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES